乳腺丝氨酸蛋白酶抑制剂
前列腺癌
DU145型
癌症研究
前列腺
癌症
小干扰RNA
细胞生长
细胞
生物
转移
细胞培养
医学
内科学
转染
遗传学
LNCaP公司
作者
Tora K Smulders-Srinivasan,Sarah Jenkinson,Laura Brown,VASILEIOS P. LENIS,Rosemary Bass
出处
期刊:Anticancer Research
[International Institute of Anticancer Research (IIAR) Conferences 1997. Athens, Greece. Abstracts]
日期:2023-11-29
卷期号:43 (12): 5331-5340
标识
DOI:10.21873/anticanres.16736
摘要
PDIA6 is a disulphide isomerase of the PDI family, known to mediate disulphide bond formation in the endoplasmic reticulum. However, PDI-related proteins also function in other parts of the cell and PDIA6 has been shown to be involved in many types of cancers. We previously identified PDIA6 as a putative Maspin interactor. Maspin has itself been implicated in prostate cancer progression. Our aim was to further explore the roles of Maspin in prostate cancer and establish whether PDIA6 is also involved in prostate cancer.RNA levels of PDIA6 and Maspin in prostate cell lines were measured using RT-PCR. Bioinformatics analysis of the TCGA database was used to find RNA levels of PDIA6 and Maspin in prostate cancer. siRNAs were used to knock-down PDIA6, and proliferation and migration assays were conducted on those cells.PDIA6 and Maspin RNA were shown to be expressed at varying levels in prostate cell lines. RNAseq data showed that PDIA6 expression was significantly increased in prostate adenocarcinoma samples, while Maspin RNA expression was decreased. When PDIA6 expression was knocked-down using siRNA in prostate cell lines, proliferation was decreased substantially in the two prostate cancer cell lines (DU145 and PC3) and also decreased in the normal prostate cell line (PNT1a), though less strongly.PDIA6 expression is higher in prostate cancer cells compared to normal prostate cells. Decreasing PDIA6 expression decreases proliferation. Thus, PDIA6 is a promising target for prostate cancer therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI